ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-794-8889 Fax: 858-259-2539


SEARCH JOBS
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

 Key Statistics


Email: hr@halozyme.com
Ownership: Public

Web Site: Halozyme Therapeutics, Inc.
Employees: 152
Symbol: HALO
 









 Company News
Halozyme Therapeutics, Inc. (HALO) Presents New Preclinical Data At AACR Annual Meeting, Announces Clinical Data Presentation At ASCO 4/20/2015 11:11:15 AM
Halozyme Therapeutics, Inc. (HALO) Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer 4/13/2015 8:02:30 AM
Halozyme Therapeutics, Inc. (HALO) Provides Update Following Type B FDA Meeting 4/8/2015 1:23:58 PM
Halozyme Therapeutics, Inc. (HALO) Appoints James Mazzola To Lead Corporate Communications, Investor Relations 3/23/2015 7:27:28 AM
Halozyme Therapeutics, Inc. (HALO) Reports Selection Of First Product Candidate Under Janssen Biotech Inc. (JNJ) Collaboration 3/10/2015 7:45:56 AM
Halozyme Therapeutics, Inc. (HALO) To Present At The Barclays 2015 Global Healthcare Conference 3/4/2015 10:24:02 AM
Halozyme Therapeutics, Inc. (HALO) Reports Fourth Quarter And Full Year 2014 Financial Results 3/3/2015 8:42:13 AM
Halozyme Therapeutics, Inc. (HALO) To Host Fourth Quarter And 2014 Year-End Financial Results Conference Call 2/24/2015 7:36:29 AM
Halozyme Therapeutics, Inc. (HALO) Announces Preclinical Study Results Of Pegph20 Published In Molecular Cancer Therapeutics 2/17/2015 7:52:12 AM
Halozyme Therapeutics, Inc. (HALO) Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors 1/21/2015 10:18:49 AM
12345678910...